Skip to Main Content

Paper Details

Applicability of US Food and Drug Administration Labeling for Dapagliflozin to Patients With Heart Failure With Reduced Ejection Fraction in US Clinical Practice: The Get With the Guidelines-Heart Failure (GWTG-HF) Registry.
JAMA Cardiol
22
2020
DAPA, Dapagliflozin, HF, HFrEF, Heart Failure, Participants, Patients, dapagliflozin, glucose, heart failure, men, participants, patients, sodium-, sodium-glucose cotransporter 2, type 1 diabetes, type 2 diabetes, women
Author NameAffiliation
Adam D DeVoreDuke Clinical Research Institute and Division of Cardiology, Duke University School of Medicine
Paul A HeidenreichStanford University School of Medicine
Karen E Joynt MaddoxWashington University School of Medicine
Pamela N PetersonDenver Health Medical Center
Gregg C FonarowAhmanson-university of california los angeles Cardiomyopathy Center, University of California
Gregg C Fonarow
Gregg C FonarowAhmanson-university of california los angeles Cardiomyopathy Center, University of California
Gregg C Fonarow
  • 1 - 8

Datasets

Release 1.2